ADS-ADEA 2016* Clinical Science
Chair: Joseph Proietto
Early weight loss responders to liraglutide 3.0 mg had greater weight loss, regression to normoglycaemia, and reduced T2D development at 3 years vs early non-responders: SCALE Obesity and Prediabetes (#245)
2:00 PM
Characteristics of individuals developing type 2 diabetes in the SCALE Obesity and Prediabetes randomised, double-blind, liraglutide vs placebo trial (#246)
2:00 PM
Weight loss and associated improvements in cardiometabolic risk factors with liraglutide 3.0 mg in the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial (#247)
2:00 PM
Gastric band surgery for overweight but not obese people is a cost-effective treatment for type 2 diabetes (#248)
2:00 PM
Salicylates intervention improves several cardiometabolic outcomes: meta-analysis of RCTs (#249)
2:00 PM
Improvement in IWQOL-Lite-derived health utility score with liraglutide 3.0 mg versus placebo over 3 years in prediabetes (#250)
2:00 PM